Press Releases Year None20222021202020192018 Sep 19, 2022 Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Sep 14, 2022 Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock Sep 13, 2022 Akero Therapeutics Announces Proposed Public Offering of Common Stock Sep 13, 2022 In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks Sep 08, 2022 Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH Aug 24, 2022 Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment Aug 04, 2022 Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Jun 27, 2022 Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis Jun 16, 2022 Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million Jun 13, 2022 Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 16
Year None20222021202020192018 Sep 19, 2022 Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Sep 14, 2022 Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock Sep 13, 2022 Akero Therapeutics Announces Proposed Public Offering of Common Stock Sep 13, 2022 In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks Sep 08, 2022 Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH Aug 24, 2022 Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment Aug 04, 2022 Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Jun 27, 2022 Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis Jun 16, 2022 Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million Jun 13, 2022 Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 16
Sep 19, 2022 Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Sep 13, 2022 In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks
Sep 08, 2022 Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH
Aug 24, 2022 Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment
Aug 04, 2022 Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Jun 27, 2022 Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis
Jun 16, 2022 Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
Jun 13, 2022 Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH
